Stem Cell Research & Therapy · 2024 · 18 citations · 38 references
EngineeringBioengineeringBiotechnologyCell TherapyCellular EngineeringRegenerative MedicineCell ManufacturingHematopoietic DevelopmentHematopoietic Stem Cell BiologyHematopoietic Stem CellsMacrophage BiologyOrganoid EngineeringBioreactor Scale-upDevelopmental HematopoiesisDrug ScreeningHematopoietic Immune Cell DevelopmentImmune Cell ManufacturingMacrophage EngineeringStem Cell-derived Immune Cells
BACKGROUND: There is a significant demand for intermediate-scale bioreactors in academic and industrial institutions to produce cells for various applications in drug screening and/or cell therapy. However, the application of these bioreactors in cultivating hiPSC-derived immune cells and other blood cells is noticeably lacking. To address this gap, we have developed a xeno-free and chemically defined intermediate-scale bioreactor platform, which allows for the generation of standardized human iPSC-derived hematopoietic organoids and subsequent continuous production of macrophages (iPSC-Mac). METHODS: We describe a novel method for intermediate-scale immune cell manufacturing, specifically the continuous production of functionally and phenotypically relevant macrophages that are harvested on weekly basis for multiple weeks. RESULTS: The continuous production of standardized human iPSC-derived macrophages (iPSC-Mac) from 3D hematopoietic organoids also termed hemanoids, is demonstrated. The hemanoids exhibit successive stage-specific embryonic development, recapitulating embryonic hematopoiesis. iPSC-Mac were efficiently and continuously produced from three different iPSC lines and exhibited a consistent and reproducible phenotype, as well as classical functionality and the ability to adapt towards pro- and anti-inflammatory activation stages. Single-cell transcriptomic analysis revealed high macrophage purity. Additionally, we show the ability to use the produced iPSC-Mac as a model for testing immunomodulatory drugs, exemplified by dexamethasone. CONCLUSIONS: The novel method demonstrates an easy-to-use intermediate-scale bioreactor platform that produces prime macrophages from human iPSCs. These macrophages are functionally active and require no downstream maturation steps, rendering them highly desirable for both therapeutic and non-therapeutic applications.
38
Disease-Specific Induced Pluripotent Stem Cells
In‐Hyun Park, Natasha Arora, Hongguang Huo et al. · Cell · 2008 · 2.2K citations · Full text
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs
Gabsang Lee, Eirini P. Papapetrou, Hyesoo Kim et al. · Nature · 2009 · 871 citations · Full text